(5-Chloro-6-(piperazin-1-yl)pyridin-3-yl)methanol → HCID 178519826, 화합물
반응식
[Br:1][C:2]1[C:10]2[N:9]=[C:8](Cl)[NH:7][C:6]=2[CH:5]=[C:4]([C:12]([F:15])([F:14])[F:13])[CH:3]=1.[Cl:16][C:17]1[CH:18]=[C:19]([CH2:29][OH:30])[CH:20]=[N:21][C:22]=1[N:23]1[CH2:28][CH2:27][NH:26][CH2:25][CH2:24]1>>[Br:1][C:2]1[C:10]2[NH:9][C:8]([N:26]3[CH2:27][CH2:28][N:23]([C:22]4[N:21]=[CH:20][C:19]([CH2:29][OH:30])=[CH:18][C:17]=4[Cl:16])[CH2:24][CH2:25]3)=[N:7][C:6]=2[CH:5]=[C:4]([C:12]([F:15])([F:14])[F:13])[CH:3]=1참가 물질
3
실험 절차
4-Bromo-2-chloro-6-trifluoromethyl-1H-benzoimidazole (180 mg, 0.6 mmol, Example 6b) reacted with (5-chloro-6-piperazin-1-yl-pyridin-3-yl)methanol (228 mg, 1 mmol, Example 60a) under. the conditions of Example 3c to give the title compound as a white solid. MS (ESI, pos. ion) m/z: 490 (M+1).
출처 및 근거
- ORD 기록
- ord-78458b2a1c904323b48a0431543840d8
- 출처 데이터셋
- uspto-grants-2009_09
- 특허 번호
- US07582761B2